Otsuka’s Sibeprenlimab Shows Promising Results in IgAN Treatment
I'm PortAI, I can summarize articles.
Otsuka Holdings Co. announced promising 12-month interim results from its Phase 3 VISIONARY trial for sibeprenlimab, a treatment for immunoglobulin A nephropathy (IgAN), showing significant reduction in proteinuria and a favorable safety profile. The company has filed a Biologics License Application with the U.S. FDA, receiving a Priority Review designation. The latest analyst rating for Otsuka's stock (JP:4578) is a Buy with a price target of Yen9366.00. Current market cap stands at Yen4415.6B, with a year-to-date price performance of -1.84%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments